Client profile: Pharmaron
Pharmaron is a premier R&D service provider for the life science industry. The company was founded in 2003 and has over 3,000 employees and operations in both China and the USA.
The company has established a broad spectrum of R&D service capabilities ranging from synthetic and medicinal chemistry, biology, DMPK, pharmacology and safety assessment to chemical and pharmaceutical development.
The company was looking to expand its service offering and establish a presence in Europe through acquisition.
Pharmaron acquired Quotient Bioresearch Group Limited, a leading provider of radiochemistry, metabolism and e-fate services based in Cardiff and Northampton. Quotient provides research and development materials, services, support and solutions to the global clients across various areas including Pharmaceutical, Agrochemical, Chemical, Biopharmaceutical and Animal Health industries.
How we helped
We supported the acquirer as follows:
- Undertaking the financial due diligence process, including liaising with the vendor’s advisers, analysing and commenting on financial information and meeting with the vendor and their advisers to discuss our findings;
- Providing specialist taxation advice in relation to Research and Development tax credits
- Liaising with legal advisers in relation to the financial aspects of all transaction documentation.
- Reviewing and liaising with the sellers in order to agree the principals for and the agreement of the completion accounts.
What the client said about us
“It was important for Pharmaron to have a financial Due Diligence provider who could work within our tight timescales and who could support our legal and commercial advisers on this important transaction for the group.MHA Broomfield and Alexander Limited were very responsive to our requirements on this transaction and helped ensure deadlines were met.”
Gilbert Li – Pharmaron Beijing Co.